Blood Parameter Changes Following Aerobic Exercise in Professional Soccer Players (ABP-Soccer)

September 11, 2026 updated by: Assoc. Prof. Dr. Özgür EKEN, Inonu University

Aerobic Exercise-Induced Changes in Ferritin, Folate, Vitamin B12, and Parathyroid Hormone Levels in Professional Soccer Players

This study aims to investigate acute changes in serum ferritin, folate, vitamin B12, and parathyroid hormone (PTH) levels following aerobic exercise in professional soccer players. Twenty professional male soccer players will voluntarily participate in the study. Participants will complete a progressive 20-meter shuttle run test. Venous blood samples will be collected immediately before and after the exercise protocol. Pre- to post-exercise changes in each blood parameter will be analyzed to determine the acute physiological responses to aerobic exercise in professional soccer players.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This single-group interventional study is designed to examine acute changes in selected blood biomarkers following aerobic exercise in professional soccer players. A total of 20 professional male soccer players aged 18-25 years will voluntarily participate. Participants will be recruited from a professional soccer club in Karabuk, Türkiye. Before participation, all individuals will receive information about the study procedures, provide written informed consent, and undergo medical screening to determine their eligibility for maximal aerobic exercise.

Body height and body mass will be measured before exercise testing. Aerobic exercise will be performed using a progressive 20-meter shuttle run test. Participants will run continuously between two lines positioned 20 meters apart while following prerecorded audio signals. Running speed will progressively increase as the interval between the audio signals decreases. The test will end when a participant fails to reach the designated line before the audio signal on two consecutive occasions.

Venous blood samples of approximately 5 mL will be collected immediately before and immediately after the exercise protocol by qualified healthcare personnel. Blood samples will be collected into anticoagulant-free serum tubes. Following a clotting period of approximately 30 minutes, the samples will be centrifuged at 3,000 revolutions per minute to separate the serum. Serum samples will be stored at -70°C until laboratory analysis.

Serum ferritin, folate, vitamin B12, and parathyroid hormone (PTH) concentrations will be measured. Pre- to post-exercise changes in each biomarker will be analyzed separately to determine the acute physiological responses elicited by aerobic exercise in professional soccer players.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: musa şahin, PhD

Study Locations

  • Turkey (Türkiye)
      • Karabük, Turkey (Türkiye)
        • Exercise Physiology Laboratory, Faculty of Sport Sciences, Karabuk University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:- Professional soccer players.

  • Willing and able to participate in the study procedures.
  • Provision of informed consent.

Exclusion Criteria:- Inability to complete the aerobic exercise protocol.

- Withdrawal from the study or unwillingness to continue participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Aerobic Exercise
All participants will complete a progressive 20-meter shuttle run test. Venous blood samples will be collected immediately before and immediately after the exercise protocol to assess acute changes in serum ferritin, folate, vitamin B12, and parathyroid hormone concentrations.
Behavioral: 20-Meter Shuttle Run Test
Participants will perform a progressive 20-meter shuttle run test by running continuously between two lines positioned 20 meters apart in time with prerecorded audio signals. Running speed will progressively increase as the interval between the audio signals decreases. The test will end when the participant fails to reach the designated line before the signal on two consecutive occasions.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Serum Ferritin Concentration From Pre-Exercise to Immediately Post-Exercise
Time Frame: Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Venous blood samples will be collected immediately before and immediately after the 20-meter shuttle run test. Serum ferritin concentration will be measured in ng/mL. For each participant, the change will be calculated by subtracting the pre-exercise value from the post-exercise value. The group-level outcome will be summarized using the mean change and standard deviation.
Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Change in Serum Folate Concentration From Pre-Exercise to Immediately Post-Exercise
Time Frame: Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Venous blood samples will be collected immediately before and immediately after the 20-meter shuttle run test. Serum folate concentration will be measured in ng/mL. For each participant, the change will be calculated by subtracting the pre-exercise value from the post-exercise value. The group-level outcome will be summarized using the mean change and standard deviation.
Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Change in Serum Vitamin B12 Concentration From Pre-Exercise to Immediately Post-Exercise
Time Frame: Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Venous blood samples will be collected immediately before and immediately after the 20-meter shuttle run test. Serum vitamin B12 concentration will be measured in pg/mL. For each participant, the change will be calculated by subtracting the pre-exercise value from the post-exercise value. The group-level outcome will be summarized using the mean change and standard deviation.
Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Change in Serum Parathyroid Hormone Concentration From Pre-Exercise to Immediately Post-Exercise
Time Frame: Immediately before exercise and immediately after completion of the 20-meter shuttle run test
Venous blood samples will be collected immediately before and immediately after the 20-meter shuttle run test. Serum parathyroid hormone (PTH) concentration will be measured in pg/mL. For each participant, the change will be calculated by subtracting the pre-exercise value from the post-exercise value. The group-level outcome will be summarized using the mean change and standard deviation.
Immediately before exercise and immediately after completion of the 20-meter shuttle run test

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Inonu University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 29, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 29, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 29, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 29, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 11, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • KBÜ-AEROBIC-BLOOD-2026-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings